https://doi.org/10.55788/9630065e
In MS, the Expanded Disability Status Scale (EDSS) score correlates relatively poorly with overall lesion load, but correlates significantly with rim-active lesion load, based on voxel-level 18 kDa translocator protein (TSPO) availability. Dr Jussi Lehto (University of Turku, Finland) and colleagues further investigated PET-measurable rim activity [1]. They included NAWM in the perilesional area and explored correlations between rim activity and biomarkers of progression, such as PET distribution volume ratio (DVR) in the NAWM, as well as overall T1 lesion load.
A total of 114 MS patients underwent MRI and [11C]PK11195 TSPO-PET. Of this cohort, 83 (73%) patients had relapsing-remitting MS and 31 (27%) had secondary progressive MS. By dilating parametric DVR maps, they obtained 0–2 mm, 2–4 mm, and 4–6 mm perilesional masks from each patient. Based on its average DVR, each 2 mm rim was categorised as HIGH or LOW. Lesions were considered BRLs if they exhibited a HIGH-HIGH-HIGH pattern within each 2 mm segment.
In 34 of 114 (38.8%) patients, BRLs were seen. Disease duration and EDSS score were significantly higher among patients with BRLs. Perhaps even more interesting, according to Dr Lehto, was that the mean [11C]PK11195 DVRs in the NAWM and thalamus were significantly higher in patients with BRLs. The proportion of BRLs correlated with overall T1-lesion volume (r=0.53; P<0.0001). Moreover, patients with ≥1 BRL did worse on almost every imaging-related biomarker of progression. Dr Lehto added that the 19 slowly progressing patients (with an EDSS score ≤1.5 after 12 years from onset) were very unlikely (11%) to have a BRL, whereas 50% of rapid progressors (EDSS score 4 after 12 years from onset) had ≥1 BRL (P=0.013). BRLs partially overlap with so-called iron-rim lesions, which are white matter lesions surrounded by a rim of iron containing microglia.
“Broad perilesional distribution of innate immune cells seen in neuropathological preparations is quantifiable in vivo with TSPO PET,” concluded Dr Letho. “Similarly to the previously categorised phenotypes ‘PET rim active’ and ‘PET-overall active,’ broad perilesional activity correlates with progression. Patients with BRLs progress more rapidly.”
- Lehto J, et al. PET-based characterization of the broad rim lesion, a novel progression-related lesion phenotype. O018, MSMilan 2023, 11–13 October, Milan, Italy.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Progressive brain tissue loss precedes the onset of clinical MS by years Next Article
New insights into the contribution of EBV to MS pathogenesis »
« Progressive brain tissue loss precedes the onset of clinical MS by years Next Article
New insights into the contribution of EBV to MS pathogenesis »
Table of Contents: MSMilan 2023
Featured articles
Letter from the Editor
Real-world data supports ocrelizumab prior to conception
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Paediatric MS
Prioritising high efficacy therapies in children with MS
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
NMOSD & MOGAD
An update on evolving treatment algorithms for NMOSD and MOGAD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause
Real-world data supports ocrelizumab prior to conception
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis
COVID-19 infection associated with higher MS relapse rate
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Curing MS
Understanding what an MS cure means and what it takes
Prodromal MS
Progressive brain tissue loss precedes the onset of clinical MS by years
Sickness absence rate increases years before clinical onset of MS
Treatment Trials and MS Strategies
Early intensive treatment enhances long-term clinical outcomes
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Biomarkers & Imaging
χ-separation can assess the effects of tissue destruction in early MS lesions
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity
Broad rim lesions correlate with a rapidly progressive MS phenotype
Smouldering inflammation detectable even in the earliest stages of MS
Related Articles
November 25, 2020
Grey matter network measures predict disability and cognition
December 9, 2021
Evobrutinib reduces relapses and MRI lesion activity
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com